中国麻风皮肤病杂志 ›› 2026, Vol. 42 ›› Issue (3): 168-171.doi: 10.12144/zgmfskin202603168

• 论著 • 上一篇    下一篇

托法替布治疗丘疹脓疱型玫瑰痤疮临床疗效分析

刘佳昀1,高国敏2,李晓瑾1,范慧萍1,王兴1,张东1,马伟元1   

  1. 1山东第二医科大学附属医院（临床医学院）皮肤科，山东潍坊，261041；2德阳市第二人民医院皮肤科，四川德阳，618000
  • 出版日期:2026-03-15 发布日期:2026-03-09

Analysis of clinical efficacy of tofacitinib in the treatment of papulopustular rosacea

LIU Jiayun1, GAO Guomin2, LI Xiaojin1, FAN Huiping1, WANG Xing1, ZHANG Dong1, MA Weiyuan1   

  1. 1 Department of Dermatology, Affiliated Hospital of Shandong Second Medical University, School of Clinical Medicine, Weifang 261041, China; 2 Department of Dermatology, the Second People's Hospital of Deyang, Deyang 618000, China
  • Online:2026-03-15 Published:2026-03-09

PDF (PC)

6

摘要： 目的：评价托法替布治疗瑰痤疮的临床疗效与安全性。方法：选取就诊于我院皮肤科门诊的不适合四环素类药物治疗的丘疹脓疱型玫瑰痤疮患者，采用随机数字表法将患者分为观察组与对照组，观察组口服托法替布治疗，对照组口服异维A酸治疗，在治疗前和治疗第2、4周分别统计两组患者研究者整体评分（IGA）、患者整体评分（PaGA）及玫瑰痤疮生活质量评分（RosQol）。结果：共收集患者47例，观察组和对照组分别有4例和3例退出实验，最终两组均有20例患者完成治疗及随访。两组在治疗前IGA、PaGA、RosQol评分无显著统计学差异（均P＞0.05）。治疗2周后，观察组IGA、PaGA、RosQol评分均显著低于对照组（P＜0.05）。治疗4周后，观察组PaGA评分显著低于对照组（P＜0.05），两组间IGA、RosQol评分差异无统计学意义(P＞0.05)。两组均未发生明显不良反应。结论：短期使用托法替布治疗丘疹脓疱型玫瑰痤疮的疗效优于异维A酸，托法替布起效更快。

关键词: 玫瑰痤疮, 丘疹脓疱型, 托法替布, 异维A酸

Abstract: Objective: To evaluate the clinical efficacy and safety of tofacitinib in the treatment of rosacea. Methods: Patients with papulopustular rosacea who were ineligible for tetracycline therapy and attended the Dermatology Outpatient Department of our hospital were enrolled. They were divided into an observation group and a control group using the random number table method. The observation group was treated with oral tofacitinib, while the control group was treated with oral isotretinoin. The Investigator's Global Assessment (IGA) score, Patient's Global Assessment (PaGA) score and Rosacea Quality of Life (RosQol) score of the two groups were recorded before treatment as well as at 2 and 4 weeks after treatment, respectively. Results: A total of 47 patients were recruited. Four patients in the observation group and three in the control group withdrew from the trial, with 20 patients in each group completing the treatment and follow-up eventually. There were no statistically significant differences in IGA, PaGA and RosQol scores between the two groups before treatment (all P＞0.05). After 2 weeks of treatment, the IGA, PaGA and RosQol scores of the observation group were significantly lower than those of the control group (P＜0.05). After 4 weeks of treatment, the PaGA score of the observation group was significantly lower than that of the control group (P＜0.05), whereas there were no statistically significant differences in IGA and RosQol scores between the two groups (P＞0.05). No obvious adverse reactions were observed in either group. Conclusion: Short-term use of tofacitinib is comparable to isotretinoin in the treatment of papulopustular rosacea, and tofacitinib exerts a faster onset of action.

Key words: rosacea, papulopustular, tofacitinib, isotretioin